Mengting Dong,Chunyang Li,Patiguli·Jiapaer,Xiaofei Li,Xiaohong Xue,Ke Jiang,Jiayu Sheng. KIF15 expression characteristics: Relevance toneo-adjuvant chemotherapy efficacy in breast cancer. Oncol Transl Med, 2021, 7: 69-75. |
KIF15 expression characteristics: Relevance toneo-adjuvant chemotherapy efficacy in breast cancer |
Received:January 13, 2021 Revised:May 04, 2021 |
View Full Text View/Add Comment Download reader |
KeyWord:breast cancer; neoadjuvant chemotherapy; KIF15; molecular subtypes |
Author Name | Affiliation | E-mail | Mengting Dong | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | nancyd33@163.com | Chunyang Li | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | | Patiguli·Jiapaer | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | | Xiaofei Li | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | | Xiaohong Xue | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | | Ke Jiang | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | | Jiayu Sheng | Department of Breast Diseases, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China | sjy1983sh@126.com |
|
Hits: 3894 |
Download times: 3998 |
Abstract: |
Objective The relationship between the expression of kinesin family member 15 (KIF15) and
clinicopathological features in breast cancer (BC) remains controversial. In this study, we aimed to explore
the influence of KIF15 expression on the efficacy of neoadjuvant chemotherapy (NAC) and evaluate its
clinical value in predicting prognosis for BC patients.
Methods Immunohistochemistry was used to detect KIF15 expression in 93 BC patients undergoing
NAC to analyze the relationship between KIF15 expression and clinical efficacy and analytical parameters.
Results Of the 93 BC patients enrolled, 24.73% who underwent NAC had higher KIF15 expression levels,
showing positive correlations with ER, HER-2, Ki67, and lymph node metastasis (P < 0.05). The clinical
benefit of NAC was 70.97%, and the major histological response (MHR) rate was 61.29%. The effective
therapeutic rate in patients with high KIF15 expression was 95.65%, while the MHR rate was 65.22%.
Various molecular BC subtypes with varied clinical and pathological responses exhibited correlation to
a large extent. Of all the BC patients studied, 84% of the triple-negative breast cancer (TNBC) patients
were evaluated as clinically effective, and 52% of the TNBC patients were evaluated as pathologically
effective, and these values were significantly higher than those of the other molecular types (P < 0.05).
The expression of KIF15 in 25 TNBC patients showed positive correlations with lymph node metastasis.
Conclusion Overexpression of KIF15 was shown to increase BC sensitivity to chemotherapy and
demonstrated better outcomes. |
Close |
|
|
|